Lubieniecki Paweł, Wołyniec Maria, Połtyn-Zaradna Katarzyna, Zatońska Katarzyna, Szuba Andrzej
Clinical Department of Diabetology and Internal Disease, Wroclaw Medical University, Borowska Street 213, 50-556 Wroclaw, Poland.
Department of Social Medicine, Wroclaw Medical University, 50-345 Wrocław, Poland.
J Clin Med. 2023 Dec 22;13(1):60. doi: 10.3390/jcm13010060.
The aim of this study is to present data on the use of lipid-lowering therapy (LLT) in relation to calculated cardiovascular risk (CVR) and an additionally defined target LDL-C concentration. The cohort consisted of 1287 participants in the Polish edition of the Prospective Urban and Rural Epidemiological Study (PURE). CVR was calculated for each participant using the SCORE2 or SCORE2-OP scale, and for patients with diabetes mellitus (DM), chronic kidney disease (CKD) or atherosclerotic cardiovascular disease (ASCVD) according to the respective criteria. In the cohort analysed, 107 of 212 people (50.5%) in the low cardiovascular risk (CVR) group, 284 of 414 people (68.6%) in the moderate CVR group, 562 of 612 people (91.8%) in the high CVR group and 48 of 49 people (98%) in the very high CVR group did not meet the target LDL-c criterion. Of those in the low CVR group, 86% of participants were not receiving lipid-lowering therapy (LLT); in the moderate CVR group, the proportion was 77.8%; in the high CVR group, 68.1% and in the very high CVR group, 75%. In each cardiovascular risk group, participants who did not meet the target LDL-c concentration criterion and did not take LLT made up the larger group.
本研究的目的是呈现与计算得出的心血管风险（CVR）以及额外定义的目标低密度脂蛋白胆固醇（LDL-C）浓度相关的降脂治疗（LLT）使用数据。该队列由波兰版前瞻性城乡流行病学研究（PURE）的1287名参与者组成。使用SCORE2或SCORE2-OP量表为每位参与者计算CVR，对于糖尿病（DM）、慢性肾脏病（CKD）或动脉粥样硬化性心血管疾病（ASCVD）患者，则根据各自的标准进行计算。在分析的队列中，低心血管风险（CVR）组的212人中有107人（50.5%）、中度CVR组的414人中有284人（68.6%）、高度CVR组的612人中有562人（91.8%）以及极高CVR组的49人中有48人（98%）未达到目标LDL-c标准。在低CVR组中，86%的参与者未接受降脂治疗（LLT）；在中度CVR组中，这一比例为77.8%；在高度CVR组中为68.1%，在极高CVR组中为75%。在每个心血管风险组中，未达到目标LDL-c浓度标准且未接受LLT的参与者占较大比例。
